Here's what Citi is saying about the CSL share price

Is CSL a share to buy? Citi thinks so…

| More on:
Happy healthcare workers in a labs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been a strong performer in recent weeks.

Since this time last month, the biotherapeutics company's shares have risen over 8% to $299.00.

Can the CSL share price keep climbing?

The good news for investors is that it may not be too late to snap up CSL shares.

According to a note out of Citi, its analysts have retained their buy rating and $340.00 price target on its shares.

Based on the current CSL share price, this implies potential upside of almost 14% for investors over the next 12 months.

What did the broker say?

Citi was pleased, but not surprised, to learn that the US Food and Drugs Administration (FDA) has approved CSL's HEMGENIX (EtranaDez) gene therapy for haemophilia B.

The broker expects this to have a neutral impact on a short term basis due to the company already being the market leader for haemophilia treatments. However, it does cement CSL's position in the market, which is good news for the long term. Citi commented:

As expected, CSL received FDA approval for its gene therapy for haemophilia B, HEMGENIX (EtranaDez), the first and only one-time gene therapy approved for haemophilia B.

Whilst an exciting new treatment option for patients, we expect HEMGENIX to be neutral on an NPV basis for CSL given 1) the cannibalization of Idelvion sales (~$650m/~6% of CSL total sales): CSL Idelvion is the current standard of care in haemophilia B with ~47% market share across key markets, and 2) in a defensive move, the therapy was licensed from uniQure in 2021 at a cost of ~US$750m (acquisition+pre-launch costs) + royalties and milestones.

CSL plans to launch HEMGENIX in the US & EU in Q1'23, but it will be a slow and gradual process as the payment models are yet to be finalized (likely to be upfront, with variations in payment models in the EU). Maintain Buy, $340 TP.

Elsewhere, Macquarie responded to the news by retaining its outperform rating and lifting its price target by 4.1% to $343.00. The broker expects the therapy to have a positive impact on its earnings over the long term and has boosted its valuation to reflect this.

Motley Fool contributor James Mickleboro has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »